New Document top_band
 
Business Standard

Dr Reddy's Lab rises 2.3%

Read more on:    Nordic Bioscience | Dr Reddys Lab
Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

Nafed seeks a 12% cut in NSEL dues

Argues that NSEL procured low quality cotton resulting into losses of Rs 12 cr to Nafed

Uttarakhand to impose 2% entry tax on sugar

Move to stop units from buying commodity from Uttar Pradesh

Markets end at record closing highs

Sensex gained over 100 points and ended at 26147.33 while the Nifty ended 27 points higher at 7,795.75.

Sensex up 100 points; Infy, TCS up 2%

Sesnex is up 93 points at 26,119 and Nifty is up 18 points at 7,786 levels

Atul Limited soars over 10% on robust Q1 earnings

Q1 net profit up 48% at Rs 59.78 crore against Rs 40.45 crore in the corresponding quarter previous year.

Back to Top